PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of togTranslational Oncogenomics
 
Transl Oncogenomics. 2008; 3: 137–149.
Published online 2008 May 29.
PMCID: PMC2854514
NIHMSID: NIHMS89695

Gene Expression Patterns in Myelodyplasia Underline the Role of Apoptosis and Differentiation in Disease Initiation and Progression

Abstract

The myelodysplastic syndromes (MDS) are clonal stem cell disorders, characterized by ineffective and dysplastic hematopoiesis. The genetic and epigenetic pathways that determine disease stage and progression are largely unknown. In the current study we used gene expression microarray methodology to examine the gene expression differences between normal hematopoietic cells and hematopoietic cells from patients with MDS at different disease stages, using both unselected and CD34+ selected cells. Significant differences between normal and MDS hematopoietic cells were observed for several genes and pathways. Several genes promoting or opposing apoptosis were dysregulated in MDS cases, most notably MCL1 and EPOR. Progression from RA to RAEB(T) was associated with increased expression of several histone genes. In addition, the RAR-RXR pathway, critical for maintaining a balance between self-renewal and differentiation of hematopoietic stem cells, was found to be deregulated in hematopoietic cells from patients with advanced MDS compared to patients with refractory anemia. These findings provide new insights into the understanding of the pathophysiology and progression of MDS, and may guide to new targets for therapy. Taken together with previous published data, the present results also underscore the considerable complexity of the regulation of gene expression in MDS.

Keywords: myelodysplasia, gene expression, apoptosis, differentiation

Introduction

The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of the hematopoietic stem cells [1, 2]. The natural history of MDS is that of progressive cytopenia with increasing transfusion needs, infectious and bleeding complications or alternatively, evolution to secondary AML [1, 2]. While relatively simple clinical and pathologic scoring systems with prognostic relevance have been developed, the molecular mechanisms involved in evolution of the disease are largely unknown [3, 4]. Identifying molecular markers of MDS may allow for a more accurate assessment of the prognosis and potentially identify new targets for therapy.

The genetic lesions so far identified in MDS incompletely describe the biology and heterogeneity of the disease. Clonal karyotypic abnormalities are observed in approximately 40–50% of patients with primary MDS, and 90% of therapy-related MDS [2, 5]. Mutations important in denovo AML, for example mutations in RAS protooncogenes and FLT3 internal tandem duplications (ITD), have been described in 5%–20% of MDS patients and are variably associated with disease progression [3, 69]. Beside overt genetic lesions, epigenetic lesions may also play a roll in the development of MDS. Hypermethylation has been described in many malignancies including MDS and may be associated with disease development, progression and prognosis [1014]. For example, p15 promoter hypermethylation has been shown to be associated with MDS progression to AML in some studies [3, 15]. However, none of these alterations are specific for MDS and the underlying molecular causes of MDS have remained poorly understood.

The vast number of genetic and epigenetic disturbances in MDS makes investigations to identify potential common pathways that may involved in disease development and progression challenging. Oligonucleotide microarrays have been found to be an excellent tool to study biology and identify potential prognostic factors in many forms of malignancies, including MDS. This platform allows examination of thousands of genes using a single sample. In the current study we used oligonucleotide microarrays to determine how the genetic expression profile differs between healthy hematopoietic cells and hematopoietic cells from patients with MDS, and to identify genes and pathways that might be relevant for MDS evolution and progression.

Materials and Methods

Patients

Mononuclear cells (N = 35) or purified CD34+ cells (N = 8) from the marrow of 43 MDS patients were studied. Patients were sub-grouped according to the French-American-British (FAB) classification [16] into refractory anemia (RA, N = 18), refractory anemia with ringed sideroblasts (RARS, N = 11), refractory anemia with excess blasts (RAEB, N = 8), and refractory anemia with excess blasts in transformation (RAEB-t, N = 1). In addition, we included one patient with unclassified MDS, one patient with a mixed MDS/myeloproliferative picture, and three patients with AML that had evolved from MDS. Three patients had 5q deletion, however not as an isolated lesion, but as part of complex cytogenetic abnormalities. Mono-nuclear (N = 10) or purified CD34+ bone marrow cells (N = 14) from 24 healthy subjects were used as controls. Samples from five normal bone marrows, four patients with low grade MDS (RARS or RA), and seven patents with high grade MDS (RAEB-1 or RAEB-2) not used in the microarray studies were used for PCR validation studies of MCL1 expression. Some of the patients had received treatment in the past, including chemotherapy, erythropoietin or thalidomide, but no treatment was given within 4 weeks of sample acquisition. All patients and healthy donors had given informed consent according to the requirements of the Institutional Review Board.

Sample preparation

Heparinized bone marrow samples were obtained by aspiration from the posterior iliac crest. Mono-nuclear cells were separated by density gradient centrifugation through Ficoll-Hypaque. CD34+ cells were purified by two rounds of high-gradient magnetic cell separation using autoMACS (Milt-enyiBiotecInc, Auburn, CA)with superparamagnetic microbead labeling of CD34+ cells. Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA.) according to the manufacturer’s protocol. All RNA samples were analyzed on an HP 2100 bio-analizer (Aglient Technologyies, Palo Alto, CA USA) to ensure the integrity of total RNA prior to use in microarray assays [17].

Oligonucleotide microarray gene expression

RNA obtained from mononuclear cells was prepared according to the standard Affymetrix protocol (GeneChip Expression Analyses Technical Manual (http;//www.affymetrix.com/support/technical/manual/expression_manual.affx). For CD34+ cells, RNA was prepared using a single stranded linear amplification protocol (SLAP) prior to RNA labeling and hybridization [17]. Fragmented, bio-tinylated cDNA was hybridized to an Affymetrix HG-U133 microarray according to the manufacturer’s protocol.

Data analysis

DAT files for individual samples were generated using Affymetrix MAS 5.0 software. Target signals for probe sets were scaled to 500 for analyses. The detection algorithm was based upon default settings per Affymetrix recommendations (https://www.affymetrix.com/support/downloads/manuals/data_analysis_fundamentals_manual.pdf).

Signals were transformed into log2 intensity. Normalization was performed using the R 2.2.1 software [18]. The expression data was then analyzed using SAM 2.2.1 (Significance Analysis of Microarrays (SAM), Stanford, CA)[19] or Gene-Plus 1.2 (http://www.enodar.com/technology6.htm) for specific gene expression analysis and Gene Set Enrichment Analysis software (GSEA v1.0, Broad Institute, MIT, Cambridge, MA) for pathway analysis [20]. We selected a false discovery rate (FDR) of 5% to determine statistically significant up or down regulated genes in SAM [21]. Hierarchical clustering was performed using the dChip software available at http://biosun1.harvard.edu/complab/dchip/.

For the analysis of MCL1 levels and transcript ratio in different MDS disease stages, a global p-value was derived using linear regression and tested in the null hypothesis that the mean transcript ratios were the same across normal, RA, and advanced phase MDS. The significant test for trend used linear regression of the mean of the transcript across each group, where each group was assigned values 1, 2, and 3 for normal, low, and advanced MDS, respectively.

PCR validation of MCL1

To validate the gene expression of MCL1 in normal and MDS hematopoesis, we developed quantitative RT-PCR assays. Samples from five normal bone marrows, four patients with low grade MDS (RARS or RA), and seven patents with high grade MDS (RAEB-1 or RAEB-2) not used in the micro-array studies were analyzed. For MCL1, the two alternative splice variants were amplified separately, producing a full-length transcript (T×1) associated with anti-apoptosis, and the alternatively spliced, smaller transcript (T×2) that is pro-apoptotic. Quantitative PCR validation for MCL1 splice variants was performed on an ABI 7900 HT Fast Real-Time PCR System. Thermocycler conditions were set at: 50 °C for 2 min, 95 °C for 10 min, and 40 cycles at 95 °C for 15 sec and 60 °C for 1 min. A common primer sequence was used for the forward MCL1 primer (E×1): 5′-GAAGGCGCTGGAGACCTTAC-3′). MCL1-T×1 (MCL1-T×1R) and MCL1-T×2 (MCL1-T×1R) reverse primer sequences were 5′-TTTCCGAAGCATGCCTTGG-3′ and 5′-ACTCCACAAACCCATCCTTGG-3′, respectively. All probes were FAM-TAMRA; the MCL-1 probe sequence was 5′-ATGGCGTGCAGCG-CAACCAC-3′. Controls genes were obtained from cloned 2.1 TOPO vector plasmids. The size of the MCL1-T×1 and MCL1-T×2 inserts was 517 bp, and 269 bp respectively.

Results

To explore the changes in gene expression that occur with the evolution of MDS from normal hematopoietic progenitor cells and during disease progression from RA to RAEB and transformation into secondary AML, we used two general strategies. First, we identified expression changes common to all MDS cases compared to normal bone marrow, and secondly, we examined gene expression in MDS cases that correlated with disease subtypes. Since it is not clear to what extent the biology of MDS is determined only by the malignant “stem cell” and what the entire cellular environment contributes, separate analyses were performed in unselected and CD34+ selected populations of both MDS and normal hematopoietic cells.

Gene expression in MDS compared to normal bone marrow

We first compared unselected marrow mononuclear cells from 35 patients with MDS and 10 healthy donors. Unsupervised hierarchical clustering showed complete segregation between normal bone marrow and MDS marrow (Fig. 1A). However, there was no segregation between the different morphologic subtypes of MDS (Fig. 1A), underscoring the difficulty of describing MDS biology by morphology alone.

Figure 1
A. Hierarchical clustering of 1,000 differentially expressed genes in normal marrow and marrow from MDS patients. Each row represents a single probe set and each column a separated normal or MDS marrow sample. Blue coloring represents down-regulated genes ...

In comparing all MDS cases to normal bone marrow, 516 genes were up-regulated and 2107 were down-regulated in the MDS samples (Supplementary Table 1). The top up-regulated genes in MDS included: the HSPA1A (heat shock 70 kDa protein), CEACAM6 (carcinoembryonic antigen-related cell adhesion), DEFA1/4 (defensin alpha 1 and 4), GFI1 (growth factor independent 1) and TCN1 (transcobalamin 1). Among the top down-regulated genes were CREM (a cAMP responsive element modulator), SC5D (sterol-C5-desaturase (ERG3 delta-5-desaturase homolog, fungal)-like), PIK3R1 (phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) and IRF4 (interferon regulatory factor 4). GSEA analysis was then used to discover annotated biological pathways over-represented by genes that were up or down-regulated in MDS compared to normal bone marrow. The pathways most significantly enriched in abnormally regulated genes in MDS were vesicle transport, glycogen metabolism, chaperone modulated interferon signaling, and the pentose phosphate pathway.

We next compared gene expression in CD34+ selected cells from MDS and normal bone marrow to examine potential changes occurring primarily in the putative MDS “stem cell”. We identified 704 genes that were up-regulated and 826 genes that were down-regulated in the CD34+ cells from MDS patients compared to CD34+ cells from healthy donors (Supplementary Table 2). In comparing the genes that differed significantly between unsorted samples and purified CD34+ cells, we observed an overlap of 12 genes that were consistently up-regulated in both the unselected and CD34+ selected cells, and 95 genes that were consistently down-regulated in both the unselected and CD34+ selected cells (Table 1, full list in Supplementary Table 3). These genes are likely to be highly relevant as markers of biological activity, as well as targets for diagnostic and therapeutic tools. The top overlap genes and their expression in all samples are shown in Figure 1B, 1C and Figure 2. The overlap genes fall into several relevant biological categories. Interestingly, many genes were deregulated in favor of increased apoptosis: decreased expression in the anti-apoptotic regulator MCL1, the erythropoetin receptor EPOR, and TNF anti-apoptotic modulator TNFAIP3, and an increased expression in Ca+2 activated nucleotidase CANT1, and the inhibitory receptor LAIR1. There was no association of EPOR level and past use of erythropoetin. Dysregulated immune function and cytokine expression have been implicated increased expression of the CD4/CD8 cytokine CCL18, the decreased expression of the “master” control gene for class II MHC expression CIITA, and the decreased expression of CXCR4, the receptor for stroma derived factor 1.

Figure 2
Expression of genes that were up- or down-regulated in MDS compared to normal bone marrow
Table 1
Top genes differentially expressed in MDS compared to normal bone marrow.

Gene expression in RA compared to advanced MDS

The signals that lead to progression from RA to more advanced disease are poorly understood. We compared unselected mononuclear cells from 16 patients with RA to unselected mononuclear cells from 11 patients with advanced MDS, again using normal bone marrow as reference. Several genes were expressed differently in normal bone marrow, RA and advanced disease (Table 2, Supplementary Table 4). Among these genes are MAX (MYC associated factor X), HIST2H2BE (histone 2, H2be), HIST2H2AA (histone 2, H2aa), HIST1H2BG (histone 1, H2bg) and TNFRSF1A (tumor necrosis factor receptor superfamily, member 1A) which were increasingly expressed with the evolution of RA from normal bone marrow and with progression from RA to more advanced stages of MDS (Fig. 3). ASGR2 (asialoglycoprotein receptor 2), TGFB1 (transforming growth factor, beta 1) IDH3B (isocitrate dehydrogenase 3 NAD+ beta) and EPB41L3 (erythrocyte membrane protein band 4.1-like 3) were down regulated in RA compared to normal bone marrow, and were further down-regulated in advanced MDS (Fig. 3). We next searched for changes in biological pathways associated with MDS disease progression. Using the GSEA software we identified statistically significant enrichment in genes involved in the Rac 1 cell motility signaling pathway and the RAR-RXR pathway with advanced disease.

Figure 3
Expression of genes that correlated with advanced disease
Table 2
Top genes differentially expressed in Advanced Disease (RAEB and RAEBT) compared to RA compared to normal bone marrow.

Validation studies of MCL1

In validation studies (Fig. 4), the expression of both the longer anti-apoptotic transcript (T×1) and the shorter pro-apoptotic transcript (T×2) variants of MCL1 decreased significantly from normal bone marrow to low grade, and high grade MDS (global significance levels of T×1 and T×2 when comparing normal, low, and high grade MDS were p = 0.03 and p = 0.007, respectively). Moreover, there was a shift of the ratio of the anti-apoptotic/pro-apoptotic mRNA level in these three states, with a T×1/T×2 of 8.4 for normal bone marrow, 4.8 for low grade MDS, and 2.6 for high grade MDS (global significance p = 0.0008, test of trend p = 0.0001). Thus, MDS and progression of MDS were associated with not only a global decline in MCL1 level, but a shift in transcript towards a pro-apoptotic bias.

Figure 4
Quantitative RT-PCR assay of MCL1

Discussion

MDS comprises a heterogeneous group of clonal disorders that are characterized by aberrant differentiation in multiple hematopoietic cell lineages and are thought to involve hematopoietic stem cells [1, 2]. However, there is mounting evidence that the disease process is not entirely stem cell-autonomous and that signals derived from more differentiated cells, in particular monocytes and T lymphocytes, and from the marrow stroma affect the disease process [2230]. We, therefore, performed an analysis of gene expression in both unselected mononuclear cells and in selected CD34+ cells from MDS marrow in comparison to the analogous cell populations from normal marrow. Our results identified 2623 genes with expression differences between unselected marrow mononuclear cells from healthy donors and MDS patients and 1530 genes with expression differences between CD34+ cells from healthy donors and MDS patients. Compared to normal marrow, MDS was associated with an aberrant expression of genes involved in apoptosis, including a decreased expression of MCL1 and EPOR1, and these changes were present both in non-selected and CD34+ selected cell populations. Moreover, the PML gene and genes of the RAR-RXR pathway were found to be associated with the diagnosis of MDS and with advanced disease, respectively, suggesting disruptions of the normal differentiation pathway.

Several genes associated with the promotion of a pro-apoptotic state were identified, including anti-apoptotic regulator MCL1, the erythropoetin receptor EPOR, and TNF anti-apoptotic modulator TNFAIP3. Down regulation of MCL1 is consistent with the increased rate of apoptosis observed in MDS [26, 3135]. The protein encoded by the MCL1 gene belongs to the Bcl-2 family, known to be regulator of programmed cell death. MCL1 has been shown to be essential in the survival of hematopoetic stem cells, as inducible deletions of MCL1 in murine models results in a profound loss of bone marrow function, including a loss of hematopoietic stem cells [36]. MCL1 activity appears to be required for neutrophil, but not for macrophage survival, [37] suggesting the possibility of lineage specific or differentiation dependent activity. Alternative splicing of the MCL1 gene results in two transcript variants encoding distinct isoforms. The longer gene product (isoform 1; T×1) enhances cell survival by inhibiting apoptosis, while the alternatively spliced shorter gene product (isoform 2; T×2) promotes apoptosis and is death-inducing [38]. These findings are reminiscent of those described for the long and short splice variants of the death signal inhibitory protein FLIP in MDS, [39] suggesting that regulation of splice variants at the transcriptional level is involved in the determination of cell death in MDS. Our data show that not only was MCL1 expression decreased in MDS compared to normal hematopoetic cells, but ratio of long/short transcripts shifted in favor of a more pro-apoptotic state. Would such a pattern be compatible with the general observation that apoptosis in marrow cells overall tends to decrease as MDS progressed to more advanced stages? [40] The results appear counterintuitive. However, we have previously shown that the rate of apoptosis differs between clonal and non-clonal hematopoietic cells, and the relative proportions of those cell populations change with progression of MDS [41]. Further we observed that expression of the short splice variant of FLIP, characterized anti-apoptotic protein, showed a positive correlation with the extent of apoptosis [39]. Taken together with the lineage specificity of MCL1 as described by Dzhagalove et al. [37] it is conceivable that a pro-apoptotic effect of MCL1 in advanced MDS is expressed only in subset of cells, but does not interfere with increasing proliferation of the malignant clone. Such a model would also be consistent with the observed overall decline in expression of this gene as MDS progresses (see results).

The erythropoietin receptor (EPOR) is a member of the cytokine receptor family. Upon erythropoietin binding, the erythropoietin receptor activates the Jak2 tyrosine kinase, which in turn activates various intracellular signaling pathways, including, Ras/MAP kinase, phosphatidylinositol 3-kinase and STAT transcription factors [42]. EPOR has an anti-apoptotic function via the Akt-pathway, and signaling via the erythropoietin receptor promotes erythroid cell survival, particularly in patients with MDS [4345]. Thus, the down-regulation of both MCL1 and EPOR may play a role in the dysregulation of apoptosis in hematopoetic cells leading to ineffective hematopoiesis in MDS. It is clear, however, that the pattern of expression of MCL1 and EPOR by themselves can not explain satisfactorily the extent of apoptosis and proliferation dysregulations at different stages of MDS. Other factors are involved, and studies of purified cell populations, simultaneously analyzing the impact of various signals will be necessary [46].

Of special biological interest are the MAX (MYC associated factor X) and PML (promyelocytic leukemia) genes, which were found to be up-regulated in both unselected mononuclear cells and CD34+ selected cells in MDS compared to normal bone marrow and which showed a correlation with progression to advanced disease. The protein encoded by the MAX gene is a transcription factor that interacts with the MYC oncoprotein to form homodimers and heterodimers. Rearrangement among these dimer forms provides a complex system of transcriptional regulation [47]. Therefore, alteration in transcription regulation resulted by up regulation of the MAX gene might play a role in the pathophysiology of MDS. In addition, the correlation with progression to advanced disease and the fact that the MAX gene was found to be up regulated in both CD34+ selected cells and unselected marrow cells make this gene a candidate marker for disease progression. The protein encoded by the PML gene is a member of the tripartite motif (TRIM) family. This phosphoprotein localizes to nuclear bodies where it functions not only as a transcription factor but also as a tumor suppressor. Its expression is cell-cycle related and regulates the p53 response to oncogenic signals [48]. The gene is also involved in the translocation of the retinoic acid receptor alpha gene associated with acute promyelocytic leukemia (APL) [49]. A Further suggestion of the importance of PML and the RARA pathway in MDS disease progression is the deregulation of the RAR-RXR pathway in the advanced MDS noted in our analysis. RXR and RAR are nuclear receptors that bind either all-trans retinoic, 9-cis retinoic acid, or other retinoid ligands [50]. Ligand binding induces a conformational change in the receptors which results in dissociation of the co-repressors and binding of co-activators with histone acetylase activity [50]. The retinoic acid pathway is critical for maintaining a balance between self-renewal and differentiation of hematopoetic stem cells, [51, 52] and deregulation of the RAR-RXR pathway, as was shown in our study, may affect differentiation and self-renewal, and thereby allow RA to progress to acute leukemia.

Three histone genes (HIST2H2BE, HIST-2H2AA, HIST1H2BG) were found to be up-regulated in MDS compared to normal bone marrow, and moreover found to be correlated with advanced disease. The expression of specific histone classes dictate changes in chromatin structure and gene expression, and influences various pathways, including cell cycle progression [5355]. In addition, there is considerable evidence that histone H1 also functions as a non-specific repressor of transcription [56]. Moreover, post-translational modifications of histones by histone acetylation and deacetylation play a role in tumorgenesis. Histone deacetylases are promising targets in drug development for cancer therapy [57]. Given that our data suggest that aberrations in histone biology are involved in MDS progression, their may be a rationale for using these agents to stem progression of early MDS, especially in combination with agents that block apoptosis, as discussed above.

Several studies have examined gene expression in MDS, using either purified CD34+ or unselected mononuclear cells [5862]. There is little overlap between the genes identified across those studies or our current results. Such discrepancies are not uncommon in gene expression studies, and likely result from differences in cell types studied (CD34+ versus mononuclear cells), analytic techniques to define significant genes, and composition of the cohorts of patients studied. For example, the study by Pellagatti et al. [60] examined CD34+ cells from 55 MDS patients obtained from multiple centers, and showed that MDS cells had gene signatures enriched in interferon response genes. Of the 55 patents, 20 had the 5q- chromosomal aberration. Patients with 5q- MDS are unusually sensitive to the drug lenalidomide, and have recently been shown to have a unique gene expression signature using unselected mononuclear cells [63].

Since it is unknown which cell population, CD34+ selected or unselected mononuclear cells, best describes the pathology of MDS, and given that various studies have used both types of samples, we performed both types of arrays, and focused on genes found to be dysregulated in both cell populations. Thus, we consider our gene selection to be fairly robust. We are comforted by the fact that the most relevant genes identified in the present analysis seem biologically relevant: alterations of differentiation and proliferation pathways (PML, RAR-RXR, MAX), involvement in apoptosis (MCL1, EPOR) and regulation of hematopoiesis (TNFAIP3, CXCR4, CCL18).

Since the patient population included in this study was relatively small, we were unable to study specific correlations between gene expression, cytogenetics, and clinical presentation. However there did not appear to be an association of previous treatment to the molecular signature, and specifically there was no effect of erythropoietin treatment on EPOR gene expression. These findings strengthen our interpretation that low EPOR levels might be related to the pathophysiology of MDS, and might explain the heterogeneity of response to treatment with erythropoietin among MDS patients.

In conclusion, this study provides new data on gene expression in the different phases of MDS. Although no single gene can likely explain the pathophysiology of the disease, some of the differences delineated in this study may prove relevant in our efforts to identify prognostic markers and therapeutic targets.

Supplementary Tables

Table S1

MDS (multiple groups) vs NBM mononuclear cells.

Table S2

MDS (multiple groups) vs NBM CD34+ cells.

Table S3

OVELAPPED GENES (up/down regulated) in MDS multiple groups vs NBM (Mononuclear cells and CD 34+ cells).

Table S4

Advanced Disease (RAEB and RAEBT) versus RA versus normal bone marrow.

Acknowledgments

We thank all the patients and healthy donors who agreed to donate marrows for these investigations.

Footnotes

Author contributions

Supported by NHI/NCI grants: HL36444, HL082941, CA18021.

Merav Bar: Conception and design, Collection and/or assembly of data, Data analysis and interpretation, Manuscript writing.

Derek Stirewalt: Conception and design, Collection and/or assembly of data, Data analysis and interpretation.

Era Pogosova-Agadjanyan: Collection and/or assembly of data.

Vitas Wagner: Collection and/or assembly of data.

Ted Gooley: Data analysis and interpretation.

Nissa abbasi: Collection and/or assembly of data.

Ravi Bhatia: Provision of study material or patients, Data analysis and interpretation.

Joachim Deeg: Conception and design, Financial support, Data analysis and interpretation, Manuscript writing.

Jeral Radich: Conception and design, Financial support, Data analysis and interpretation, Manuscript writing.

References

1. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998 Jan;83(1):71–86. [PubMed]
2. Heaney ML, Golde DW. Myelodysplasia. N. Engl. J. Med. 1999 May 27;340(21):1649–60. [PubMed]
3. Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. International journal of hematology. 2001 Jun;73(4):429–37. [PubMed]
4. Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo. Clin. Proc. 2005 Jan;80(5):681–98. [PubMed]
5. Olney HJ, Le Beau MM. The cytogenetics of myelodysplastic syndromes. Best Pract Res. Clin. Haematol. 2001 Sep;14(3):479–95. [PubMed]
6. Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin. Hematol. 1996 Apr;33(2):127–38. [PubMed]
7. Horiike S, Misawa S, Nakai H, Kaneko H, Yokota S, Taniwaki M, et al. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia. 1994 Aug;8(8):1331–6. [PubMed]
8. Neubauer A, Greenberg P, Negrin R, Ginzton N, Liu E. Mutations in the ras protooncogenes in patients with myelodysplastic syndromes. Leukemia. 1994 Apr;8(4):638–41. [PubMed]
9. Shih LY, Lin TL, Wang PN, Wu JH, Dunn P, Kuo MC, et al. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Cancer. 2004 Sep 1;101(5):989–98. [PubMed]
10. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur. J. Haematol. 2006 Jan;76(1):23–32. [PubMed]
11. Guan X, Sagara J, Yokoyama T, Koganehira Y, Oguchi M, Saida T, et al. ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma. Int. J. Cancer. 2003 Nov 1;107(2):202–8. [PubMed]
12. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003 Nov 20;349(21):2042–54. [PubMed]
13. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002 Jun;3(6):415–28. [PubMed]
14. Machida EO, Brock MV, Hooker CM, Nakayama J, Ishida A, Amano J, et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res. 2006 Jun 15;66(12):6210–8. [PubMed]
15. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998 Apr 15;91(8):2985–90. [PubMed]
16. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. British journal of haematology. 1982 Jun;51(2):189–99. [PubMed]
17. Stirewalt DL, Pogosova-Agadjanyan EL, Khalid N, Hare DR, Ladne PA, Sala-Torra O, et al. Single-stranded linear amplification protocol results in reproducible and reliable microarray data from nanogram amounts of starting RNA. Genomics. 2004 Feb;83(2):321–31. [PubMed]
18. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: 2008.
19. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. 2001 Apr 24;98(9):5116–21. [PubMed]
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 2005 Oct 25;102(43):15545–50. [PubMed]
21. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U.S.A. 2003 Aug 5;100(16):9440–5. [PubMed]
22. Aizawa S, Nakano M, Iwase O, Yaguchi M, Hiramoto M, Hoshi H, et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk. Res. 1999 Mar;23(3):239–46. [PubMed]
23. Copplestone JA, Mufti GJ, Hamblin TJ, Oscier DG. Immunological abnormalities in myelodysplastic syndromes. II. Coexistent lymphoid or plasma cell neoplasms: a report of 20 cases unrelated to chemotherapy. British journal of haematology. 1986 May;63(1):149–59. [PubMed]
24. Deeg HJ, Beckham C, Loken MR, Bryant E, Lesnikova M, Shulman HM, et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk. Lymphoma. 2000 Apr;37(3–4):405–14. [PubMed]
25. Flores-Figueroa E, Arana-Trejo RM, Gutierrez-Espindola G, Perez-Cabrera A, Mayani H. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk. Res. 2005 Feb;29(2):215–24. [PubMed]
26. Liesveld JL, Jordan CT, Phillips GL. The hematopoietic stem cell in myelodysplasia. Stem Cells. 2004;22(4):590–9. [PubMed]
27. Micheva I, Thanopoulou E, Michalopoulou S, Karakantza M, Kouraklis-Symeonidis A, Mouzaki A, et al. Defective tumor necrosis factor alpha-induced maturation of monocyte-derived dendritic cells in patients with myelodysplastic syndromes. Clin. Immunol. 2004 Dec;113(3):310–7. [PubMed]
28. Miura I, Kobayashi Y, Takahashi N, Saitoh K, Miura AB. Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting. British journal of haematology. 2000 Sep;110(4):876–9. [PubMed]
29. Tauro S, Hepburn MD, Bowen DT, Pippard MJ. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica. 2001 Oct;86(10):1038–45. [PubMed]
30. van Lom K, Hagemeijer A, Smit E, Hahlen K, Groeneveld K, Lowenberg B. Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage. Leukemia. 1995 Nov;9(11):1818–21. [PubMed]
31. Albitar M, Manshouri T, Shen Y, Liu D, Beran M, Kantarjian HM, et al. Myelodysplastic syndrome is not merely “preleukemia” Blood. 2002 Aug;100(3):791–8. [PubMed]
32. Bouscary D, Chen YL, Guesnu M, Picard F, Viguier F, Lacombe C, et al. Activity of the caspase-3/CPP32 enzyme is increased in “early stage” myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp. Hematol. 2000 Jul;28(7):784–91. [PubMed]
33. Pecci A, Travaglino E, Klersy C, Invernizzi R. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow. Acta. Haematol. 2003;109(1):29–34. [PubMed]
34. Shimazaki K, Ohshima K, Suzumiya J, Kawasaki C, Kikuchi M. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. British journal of haematology. 2000 Sep;110(3):584–90. [PubMed]
35. Washington LT, Jilani I, Estey E, Albitar M. Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia. Leuk. Res. 2002 Oct;26(10):899–902. [PubMed]
36. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science, (New York, NY) 2005 Feb 18;307(5712):1101–4. [PubMed]
37. Dzhagalov I, St John A, He YW. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood. 2007 Feb 15;109(4):1620–6. [PubMed]
38. Michels J, Johnson PW, Packham G. Mcl-1. Int. J. Biochem. Cell Biol. 2005 Feb;37(2):267–71. [PubMed]
39. Benesch M, Platzbecker U, Ward J, Deeg HJ, Leisenring W. Expression of FLIP(Long) and FLIP(Short) in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia. 2003 Dec;17(12):2460–6. [PubMed]
40. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. British journal of haematology. 1998 Oct;103(1):176–88. [PubMed]
41. Li X, Bryant CE, Deeg HJ. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. International journal of hematology. 2004 Aug;80(2):140–5. [PubMed]
42. Cheung JY, Miller BA. Molecular mechanisms of erythropoietin signaling. Nephron. 2001 Mar;87(3):215–22. [PubMed]
43. Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, et al. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Molecular cancer therapeutics. 2006 Feb;5(2):356–61. [PubMed]
44. Hellstrom-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Curr. Hematol. Rep. 2003 Mar;2(2):122–9. [PubMed]
45. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British journal of haematology. 2003 Mar;120(6):1037–46. [PubMed]
46. Stirewalt DL, Mhyre AJ, Marcondes M, Pogosova-Agadjanyan E, Abbasi N, Radich JP, et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS. British journal of haematology. 2008 Feb;140(4):444–53. [PubMed]
47. Lee LA, Dang CV. Myc target transcriptomes. Curr. Top Microbiol. Immunol. 2006;302:145–67. [PubMed]
48. Zimber A, Nguyen QD, Gespach C. Nuclear bodies and compartments: functional roles and cellular signalling in health and disease. Cell Signal. 2004 Oct;16(10):1085–104. [PubMed]
49. Melo RA, de Vasconcellos JF, Melo FC, Machado CG, Lacerda TM, Souto FR. PML-RARalpha fusion gene transcripts and biological features in acute promyelocytic leukemia patients. Clin. Lab Haematol. 2006 Apr;28(2):126–9. [PubMed]
50. Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene. 2004 Mar 17;328:1–16. [PubMed]
51. Johnson BS, Mueller L, Si J, Collins SJ. The cytokines IL-3 and GM-CSF regulate the transcriptional activity of retinoic acid receptors in different in vitro models of myeloid differentiation. Blood. 2002 Feb 1;99(3):746–53. [PubMed]
52. Purton LE, Dworkin S, Olsen GH, Walkley CR, Fabb SA, Collins SJ, et al. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J. Exp. Med. 2006 May 15;203(5):1283–93. [PMC free article] [PubMed]
53. Gunjan A, Verreault A. A Rad53 kinase-dependent surveillance mechanism that regulates histone protein levels in S. cerevisiae. Cell. 2003 Nov 26;115(5):537–49. [PubMed]
54. Quina AS, Buschbeck M, Di Croce L. Chromatin structure and epigenetics. Biochem. Pharmacol. 2006 Jul 10; [PubMed]
55. Quivy JP, Almouzni G. Rad53: a controller ensuring the fine-tuning of histone levels. Cell. 2003 Nov 26;115(5):508–10. [PubMed]
56. Brown DT, Alexander BT, Sittman DB. Differential effect of H1 variant overexpression on cell cycle progression and gene expression. Nucleic Acids Res. 1996 Feb 1;24(3):486–93. [PMC free article] [PubMed]
57. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer. 2006 Jan;6(1):38–51. [PubMed]
58. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood. 2002 Nov 15;100(10):3553–60. [PubMed]
59. Lee YT, Miller LD, Gubin AN, Makhlouf F, Wojda U, Barrett AJ, et al. Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays. Blood. 2001 Sep 15;98(6):1914–21. [PubMed]
60. Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Della Porta MG, Killick S, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon stimulated genes and correlation to FAB. subtype and karyotype. Blood. Mar. 2006;9 [PubMed]
61. Pellagatti A, Esoof N, Watkins F, Langford CF, Vetrie D, Campbell LJ, et al. Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. British journal of haematology. 2004 Jun;125(5):576–83. [PubMed]
62. Pellagatti A, Fidler C, Wainscoat JS, Boultwood J. Gene expression profiling in the myelodysplastic syndromes. Hematology. 2005 Aug;10(4):281–7. [PubMed]
63. Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J, et al. An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome. PLoS medicine. 2008 Feb 12;5(2):e35. [PMC free article] [PubMed]

Articles from Translational Oncogenomics are provided here courtesy of SAGE Publications